Novartis Ag

Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed

Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria

Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)

Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants

Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030